HIV-HCV Coinfection
•
HIV-HCV Coinfection Main Page
Index of HIV-HCV Coinfection Articles by Topic
Acute HCV in HIV Coinfection
Adherence (HCV Drugs) / Adherence
Age
ALT (alanine aminotransferase)
ALT flares
AST (aspartate aminotransferase)
Anemia (ribavirin-related)
APRICOT Trial (HAART plus Pegasys/Copegus)
Body Mass Index
CD3+, CD8+, CD4+ Cells/ Cell Count
Children and Infants
Cirrhosis / Cirrhotic Patients
Clinical Trials
Cognitive Functioning
Combination Therapy
Conferences/ Workshops on HIV-HCV Coinfection
Depression (HCV-related)
Developing Countries
Discontinuation of HAART or HCV Therapy in Coinfected Patients
Dosing (standard interferons)
Dosing (peginterferons: Pegasys or Peg Intron)
Dosing (ribavirin)
Dosing (HIV drugs)
Drug Interactions
End-of-Treatment Response (ETR)
Epidemiology
Erythropoietin
Experimental Treatments
Extrahepatic Complications
FDA-approved Anti-HCV Treatments
FDA-approved Anti-HIV Treatments
FDA-approved HIV-HCV Coinfection Treatments
Fibrosis / Fibrosis progression
Filgrastim
DNA Polymorphisms
Gay Men
Genotypes (general)
Genotypes 1 and 4
Genotypes 2 and 3
Genotypes (multiple coinfection)
Genotypes non 1,2,3,4
Growth Factors
Guidelines for Treatment of HCV
HAART
HAART and Hepatotoxicity
HAART (PI-based)
HCV Clearance (eradication)
HCV as Cofactor for HIV Disease Progression
HCV Core Antigen
HCV Disease Progression
HCV Drug-related Toxicities/Side Effects
Pegasys/ Copegus
Peg Intron / Rebetol
HCV Mortality in HCV-HIV Coinfection
HCV RNA (HCV Viral Load)
HCV-related brain damage
HCV Quantitative Assay (TRAK-C)
HCV Viral Load
Hemophilia
Hepatic Decompensation / Hepatic impairment
Hepatocellular Carcinoma (HCC)
Hepatomegaly
Histological Response (HR) Rate / Histologic Progression
HIV-HCV-HBV triple coinfection
HIV as Cofactor for HCV Disease Progression
HIV Disease Progression
HIV Drug-related Toxicities/Side Effects
HIV RNA (HIV viral load)
Immune Responses / Immune Restoration
Immune Suppression
Injection Drug Users (IDU)
Interferon (IFN): standard interferon alfa-2a (Roferon A)
Interferon (IFN): standard interferon alfa-2b (Intron A)
Interleukin-2 (IL-2)
Jaundice
Lipodystrophy in HIV-HCV Coinfection
Liver Biopsy
Liver Disorders
Liver Failure
Liver Histology
Liver Toxicity (HCV drug-related)
Liver Toxicity (HAART-related)
Liver-related Death
Liver Transplantation
Mitochondrial Toxicity
Morbidity (HCV- or HIV-related)
Non-invasive laboratory Index
Nonresponders
Ophthalmic (eye-related) Pathology from interferon Therapy
Pegasys (peginterferon alfa-2a) plus Copegus (ribavirin) Combination Therapy
Pegasys/Copegus and Intron A/ Rebetol: Toxicity / Side Effects
Peginterferon Alfa-2a
Peg Intron (peginterferon alfa-2b) plus Rebetol (ribavirin)
Peg Intron / Rebetol and Intron A / Rebetol Toxicity / Side Effects
Pharmacokinetics (HIV drugs
)
Pharmacokinetics (HCV drugs)
PRESCO Trial
Prevalence of HIV-HCV Coinfection
Prevalence of HCV
Psychiatric (mental) Disorders
Quality of Life
Recurrent HCV
Reports on Conferences and Workshops
Resistance of HCV to Peginterferon /Ribavirin
Retreatment (FDA-approved) of Nonresponders w/ Pegasys/Copegus
RIBAVIC Trial (HAART plus Peg Intron/Rebetol)
Ribavirin
Ribavirin Dosing
Safety
Side Effects
Steatosis
"Stopping Rule" (discontinuation of therapy) at 12 weeks)
Substance Abuse
Survival
Sustained Virological Response (SVR) / Early Virological Response (EVR)
Test for HCV
Test for HIV
Transplantation (liver)
Treatment Guidelines
Treatment Interruptions of HAART
Treatment of HCV in HIV-HCV Coinfection: FDA-approved
Treatment of HCV in HIV-HCV Coinfection: Experimental
Viral Kinetics (HCV) / Early HCV Kinetics / HCV Decay
Weight-based Dosing
Weight-based Dosing of Peg Intron and Rebetol
Women
Youth
HOME Page
HCV Main Page
HCV Index of Topics
HIV/AIDS Main Page
HIV/AIDS Index of Topics
HCV and HCV-Drug Related
Adverse Events
•
Anemia
•
Arrhythmias
•
Cirrhosis
•
CNS disorders
•
Cryoglobulinemia
•
Diabetes
•
Extrahepatic condition
•
Fibrosis
•
Fibromyalgia
•
General
•
Hearing Loss
•
Hemotological Disorders
•
Kidney Disorders
•
Neuropathy
•
Neutropenia
•
Psychiatric
•
Retinopathy
•
Skin Reaction
•
Steatosis
•
Visual Disorders
HIV and HIV-Drug Related
Adverse Events
•
Abacavir Sensitivity Reaction
•
Abdominal Pain
•
Anemia / Fatigue
•
Antidepressants
•
Bone Disorders
•
Central Nervous System (CNS)
•
Cerebrospinal Fluid (CSF)
•
Dementia
•
Depression
•
Diarrhea / GI Symptoms
•
Elevated bilirubin and Jaundice
•
Flu / Fever
•
Fungal Infections
•
Growth Failure
•
Gynecomastia
•
Hepatotoxicity (Liver Toxicity)
•
Hypertension
•
Injection Site Reactions
•
Lactic Acidosis
/
Hyperlactatemia
•
Mitochondrial Toxicity
•
Mitochondrial DNA (mtDNA)
•
Myelopathy
•
Myalgias (muscle aches)
•
Nausea / Vomiting
•
Neurotoxicity
•
Pain and Palliative Care
•
Pancreatitis
•
Peripheral Neuropathy
•
Post-traumatic Stress Disorder (PTSD)
•
Proteinuria and Elevated Creatinine Level
•
Psychiatric (mental) Disorders
•
Renal (Kidney) Toxicity / Failure
•
Sexual Dysfunction
•
Severe Adverse Drug Reactions (SADR)
•
Skin Conditions
•
Stroke
•
Suicidal Ideation
•
thrombosis / thrombocytopenia
